key: cord-1020085-wuwt9d1z
authors: Gupta, Rahul
title: Anakinra: a silver lining in COVID-19?
date: 2020-10-06
journal: Crit Care
DOI: 10.1186/s13054-020-03312-8
sha: 2cb7bccba66592a3811e0a925baf2e670b5e3a16
doc_id: 1020085
cord_uid: wuwt9d1z

nan

In the recent review article Blocking IL-1 to prevent respiratory failure in COVID-19 by Dr. Veerdonk and Dr. Netea [1] , they have implicated the importance IL-1 signaling in severe COVID-19 pathogenesis and proposed anakinra as a therapeutic intervention. I would like to humbly add some views to it; in severe COVID-19 pathology, higher amounts of microthrombi deposition can lead to the blockage in the capillaries and arteries culminating in hypoxic condition and ensuing necrosis-like events. In fact, autopsy studies have reported necrotic events of lung pneumocytes in severe COVID-19 patients [2] . Also, high serum levels of receptor-interacting protein kinase 3 (RIPK-3) in severe patients corroborate necroptosis too [3] .

The damage-associated molecular pattern IL-1α (alarmin) liberated by necrotizing lung epithelial cells could be one of the initial cytokine produced during COVID-19 pathogenesis [4] . IL-1α by further engagement to IL-1R lead to the production of an array of chemokines and cytokines [4] . IL-1β, IL-6, TNF-α, GM-CSF, IL-17, CXC chemokines, CCL chemokines, etc. are some of the few upregulated cytokines/chemokines in severe COVID-19 responsible for exacerbating the lung pathophysiology by fueling up infiltration of macrophages/neutrophils, hypercoagulability, and fibrosis phenomena [1] . Interestingly, IL-17, IL-6, GM-CSF, HIF-α, and CXC chemokines are regulated by IL-1β. The hypercoagulability with thromboembolic indications in severe patients is attributed to platelet activation and platelet monocyte aggregation, leading to the induction of tissue factor (TF) [5] . Also, IL-1β is known to positively regulate TF expression. Taming the cytokine storm can be an effective management strategy and IL-1 signaling might play a crucial role in the pathogenesis of the disease. It could be initial necrosis liberating IL-1α, which drives amplifying inflammation loop eventually leading to inflammasome-dependent pyroptosis determining the severity of the disease. Anakinra (IL-1α and IL-1β blocker) has shown greatly reduced mortality, need for invasive mechanical ventilation, and bettering oxygenation status in severe COVID-19 patients in smaller clinical studies [1] . Hence, anakinra might be effective in managing the severe pandemic state; more so, it is a well-tolerated molecule with no adverse effects. Larger controlled clinical trials with anakinra are much warranted to test the efficacy unequivocally.

Blocking IL-1 to prevent respiratory failure in COVID-19. Crit Care

Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study

Serum levels of receptor-interacting protein kinase-3 in patients with COVID-19. Crit Care

Interleukin 1α and the inflammatory process

Platelet activation and platelet-monocyte aggregates formation trigger tissue factor expression in severe COVID-19 patients

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations

Rahul is very grateful to Dr. Kate Fitzgerald and Dr. Doug Golenbock (UMASSMED) for the initial insightful discussion.

Received: 10 September 2020 Accepted: 27 September 2020